Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China
By Chaomin Wu, Xiaoyan Chen, Yanping Cai, Jia’an Xia, Xiaoping Zhou, Shan Xu, Hanping Huang, Li Zhang, Xia Zhou, C. Du and 15 more. JAMA Internal Medicine, 2020
7,521 citations recorded by the source corpus.
Importance Coronavirus disease 2019 (COVID-19) is an emerging infectious disease that was first reported in Wuhan, China, and has subsequently spread worldwide. Risk factors for the clinical outcomes of COVID-19 pneumonia have not yet been well delineated. Objective To describe the clinical characteristics and outcomes in patients with COVID-19 pneumonia who developed acute respiratory distress syndrome (ARDS) or died. Design, Setting, and Participants Retrospective cohort study of 201 patients with confirmed COVID-19 pneumonia admitted to Wuhan Jinyintan Hospital in China between December 25, 2019, and January 26, 2020. The final date of follow-up was February 13, 2020. Exposures Confirmed COVID-19 pneumonia. Main Outcomes and Measures The development of ARDS and death. Epidemiological, demographic, clinical, laboratory, management, treatment, and outcome data were also collected and analyzed. Results Of 201 patients, the median age was 51 years (interquartile range, 43-60 years), and 128 (63.7%) patients were men. Eighty-four patients (41.8%) developed ARDS, and of those 84 patients, 44 (52.4%) died. In those who developed ARDS, compared with those who did not, more patients presented with dyspnea (50 of 84 [59.5%] patients and 30 of 117 [25.6%] patients, respectively [difference, 33.9%; 95% CI, 19.7%-48.1%]) and had comorbidities such as hypertension (23 of 84 [27.4%] patients and 16 of 117 [13.7%] patients, respectively [difference, 13.7%; 95% CI, 1.3%-26.1%]) and diabetes (16 of 84 [19.0%] patients and 6 of 117 [5.1%] patients, respectively [difference, 13.9%; 95% CI, 3.6%-24.2%]). In bivariate Cox regression analysis, risk factors associated with the development of ARDS and progression from ARDS to death included older age (hazard ratio [HR], 3.26; 95% CI 2.08-5.11; and HR, 6.17; 95% CI, 3.26-11.67, respectively), neutrophilia (HR, 1.14; 95% CI, 1.09-1.19; and HR, 1.08; 95% CI, 1.01-1.17, respectively), and organ and coagulation dysfunction (eg, higher lactate dehydrogenase [HR, 1.61; 95% CI, 1.44-1.79; and HR, 1.30; 95% CI, 1.11-1.52, respectively] and D-dimer [HR, 1.03; 95% CI, 1.01-1.04; and HR, 1.02; 95% CI, 1.01-1.04, respectively]). High fever (≥39 °C) was associated with higher likelihood of ARDS development (HR, 1.77; 95% CI, 1.11-2.84) and lower likelihood of death (HR, 0.41; 95% CI, 0.21-0.82). Among patients with ARDS, treatment with methylprednisolone decreased the risk of death (HR, 0.38; 95% CI, 0.20-0.72). Conclusions and Relevance Older age was associated with greater risk of development of ARDS and death likely owing to less rigorous immune response. Although high fever was associated with the development of ARDS, it was also associated with better outcomes among patients with ARDS. Moreover, treatment with methylprednisolone may be beneficial for patients who develop ARDS.
Subfields: Infectious Diseases, Molecular Biology, Neurology
View Paper: https://www.semanticscholar.org/paper/ae968d4d9c013c78c9cde788bc1085b380150d1e
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Infectious Diseases
In Molecular Biology
In Neurology
Citations in the corpus
- Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City: a prospective cohort study (2020, background): “Survivors and non-survivors had a median of 14 (12-18) and 5 (IQR 3-10) days of IMV, respectively.”
- Coronavirus Diseases (COVID-19) Current Status and Future Perspectives: A Narrative Review (2020, background): “The period from the onset of COVID-19 symptoms to death ranges from 6 to 41 days with a median of 14 days [27].”
- Targeting potential drivers of COVID-19: Neutrophil extracellular traps (2020, neutral): “…of IL1β, IL2, IL6, IL7, IL8, IL10, IL17, IFNγ, IFNγ-inducible protein 10, monocyte chemoattractant protein 1 (MCP1), G-CSF, macrophage inflammatory protein 1α, and TNFα (Huang et al., 2020; Mehta et al., 2020; Ruan et al., 2020; Wu et al., 2020; Wu and Yang, 2020; Zhang et al., 2020).”
- Assessing nitrogen dioxide (NO2) levels as a contributing factor to coronavirus (COVID-19) fatality (2020, background): “Early studies concluded that the risk factors associated with the development of the disease are older age (Wu et al., 2020), history of smoking (Liu et al.”
- Immune Response, Inflammation, and the Clinical Spectrum of COVID-19 (2020, background): “The latter includes, among other variables, age and the existence of comorbidities that may directly affect the immune system (8, 48).”
- Comorbidity and its Impact on Patients with COVID-19 (2020, background): “5, case mortality increased as the patient’s age increased [21, 23].”